ALX Oncology Holdings Inc. — Q1 2024 Form 10-Q
Business context and period: Clinical-stage immuno-oncology company developing therapies targeting the CD47 checkpoint. This summary covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. The company has no approved products and generated no product revenue.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Prior comparison |
|---|---|---|
| Revenue | $0 from product sales | $0 from product sales |
| Research and development expense | $31.7 million | $24.8 million; up 28% |
| General and administrative expense | $6.0 million | $7.4 million; down 19% |
| Total operating expenses / operating loss | $37.8 million | $32.2 million |
| Net loss | $35.6 million; $0.71 per share | $30.2 million; $0.74 per share |
| Operating cash flow | $(37.9) million | $(27.8) million |
| Cash, cash equivalents and investments | $184.5 million | $218.1 million at December 31, 2023 |
| Current assets / current liabilities | $167.9 million / $32.2 million | $188.7 million / $36.0 million at December 31, 2023 |
| Term loan | $9.7 million net carrying value; $10.6 million future principal maturities | $9.6 million net at December 31, 2023 |
Operating margin is not meaningful because the company has no product revenue. Cash and investments declined during the quarter; cash, cash equivalents and restricted cash decreased by $8.4 million to $14.1 million. Investing cash inflow of $26.5 million mainly reflected investment maturities, rather than operating earnings. Total liabilities were $48.5 million and stockholders’ equity was $164.2 million at quarter-end.
Material changes versus Q1 2023
- Net loss increased 18%, primarily as R&D expense rose $7.0 million. Management attributed the increase mainly to more active trials and enrollment, clinical-material manufacturing, personnel and stock compensation, and a $1.0 million ScalmiBio development milestone.
- G&A expense fell 19%, partly due to a reclassification of stock-based compensation from G&A to R&D following the former CEO’s role change, and lower personnel and insurance costs.
- Net loss per share improved to $0.71 from $0.74, while weighted-average shares increased to 50.1 million from 40.9 million.
- Net cash used in operations increased to $37.9 million from $27.8 million.
Outlook, programs and risks
- Management expects significant expenses and losses to continue as it advances evorpacept and other programs. It estimates that cash, investments, subsequent ATM proceeds and the ability to draw up to an additional $40 million under the term loan will fund operations into Q1 2026. This is an estimate based on assumptions; actual cash use could be faster. The additional loan availability is subject to agreement terms, including ASPEN-06-related conditions.
- After quarter-end, the company sold 1,794,091 shares through its ATM program for approximately $26.2 million net proceeds, providing additional liquidity but diluting existing holders. During Q1, it sold 211,819 shares for $3.0 million net.
- Management reported positive prespecified interim Phase 2 ASPEN-06 results in advanced HER2-positive gastric/GEJ cancer: confirmed response rate was 52% for the evorpacept combination versus 22% for control; median duration of response was not reached versus 7.4 months. These interim results are preliminary and may change; the filing notes the study is continuing.
- The company said ASPEN-02 did not support advancing evorpacept with azacitidine to Phase 2 and that it no longer plans to pursue combinations based on that mechanism. Resources are being redirected to antibody and PD-1/PD-L1 combination programs.
- FDA cleared the ALTA-002 IND in March 2024 for a Phase 1 study in advanced solid tumors. Separately, an investigator-sponsored trial reported in April 2024 a 94% best response rate and 83% complete response rate among 18 patients with indolent relapsed/refractory B-cell lymphoma; these are collaborator-reported clinical results, not company financial guidance.
- Key risks include clinical-trial failure or delay, reliance on third-party manufacturers and research providers, the need for future capital and potential dilution, competition, adverse effects, and intellectual-property challenges. The filing reports no pending or threatened litigation at March 31, 2024. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
Investor facts to verify
- Review subsequent ASPEN-06 data and trial progress, including whether interim response and duration results are confirmed in later analyses.
- Track operating cash burn against the company’s Q1 2026 runway estimate, including the assumptions behind future spending and loan availability.
- Confirm ATM share issuance, net proceeds and remaining capacity, and assess dilution alongside outstanding options, RSUs, PSUs and pre-funded warrants.
- Monitor execution and costs of the clinical pipeline, including ALTA-002’s Phase 1 launch and the company’s decision to discontinue the azacitidine combination strategy.
- Assess term-loan conditions, interest-rate exposure and repayment obligations, as well as manufacturing commitments and potential intellectual-property constraints.